SCHEMBL14306017

SCHEMBL14306017

COc1cccc(C(=O)/C=C/c2ccc([N+](=O)[O-])cc2)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 1/20 0.78
▸ MAPT P10636 7/20 0.76
▸ LMNA P02545 5/20 0.76
▸ ALDH1A1 P00352 5/20 0.76
▸ MAOB P27338 4/20 0.73
▸ MAOA P21397 2/20 0.73
▸ NPC1 O15118 2/20 0.67
▸ RAB9A P51151 2/20 0.67
▸ HTT P42858 2/20 0.67
▸ KMT2A Q03164 2/20 0.66
▸ TDP1 Q9NUW8 2/20 0.66
▸ PAX8 Q06710 1/20 0.66
▸ SMN1; SMN2 Q16637 1/20 0.66
▸ MEN1 O00255 1/20 0.66
▸ CYP1A2 P05177 1/20 0.66
▸ CYP3A4 P08684 1/20 0.66
▸ CYP2D6 P10635 1/20 0.66
▸ CYP2C9 P11712 1/20 0.66
▸ CYP2C19 P33261 1/20 0.66
▸ BCHE P06276 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14306019 0.89 MAPT (0.91) ABCG2MAPTLMNAALDH1A1MAOB
SCHEMBL14318106 0.88 MAOB (0.78) ABCG2MAPTLMNAALDH1A1MAOB
SCHEMBL1180393 0.85 ABCG2 (0.94) ABCG2MAPTLMNAALDH1A1MAOB
SCHEMBL12871329 0.85 ABCG2 (0.94) ABCG2MAPTLMNAALDH1A1MAOB
SCHEMBL10658782 0.84 MAOB (1.00) MAPTLMNAALDH1A1MAOBMAOA
SCHEMBL14435873 0.84 MAOB (1.00) MAPTLMNAALDH1A1MAOBMAOA
SCHEMBL10658787 0.84 MAOB (1.00) MAPTLMNAALDH1A1MAOBMAOA
SCHEMBL31326032 0.84 MAOB (1.00) MAPTLMNAALDH1A1MAOBMAOA
SCHEMBL7366612 0.84 PTPN1 (0.82) MAPTLMNAALDH1A1MAOBMAOA
SCHEMBL7454702 0.84 PTPN1 (0.82) MAPTLMNAALDH1A1MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3333153-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) 2018-06-13 — — EP disclosed
US-20140171503-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER HUMAN SERVICES (US) 2014-06-19 — — US disclosed
US-20140171503-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER HUMAN SERVICES (US) 2014-06-19 — — US disclosed
WO-2012174436-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2012-12-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171503-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER AR, NCOA1, NR5A1 ABCG2 742/4885MAPT 4183/4885LMNA 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback